SCHEMBL7424121

SCHEMBL7424121

c1cnc2c(c1)C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21479447 0.93 ALOX15 (0.40)
Formic Acid SCHEMBL27997365 0.87 TRIM24 (0.39)
SCHEMBL9948370 0.87 ALOX15 (0.36)
SCHEMBL7255805 0.84 CYP2A6 (0.45)
SCHEMBL20206843 0.84 CYP1A2 (0.52)
SCHEMBL30701903 0.84 CES1 (0.39)
SCHEMBL9948344 0.82 CCR1 (0.41)
SCHEMBL27027257 0.80 NOS3 (0.38)
SCHEMBL27027264 0.79 ALDH1A1 (0.46)
SCHEMBL27027261 0.79 ALDH1A1 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11065235-B2 Substituted methanopyrido [2, 1-a] isoindolones as mAChR modulators for treating various associated pathophysiological conditions and process for preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2021-07-20 US claimed
CN-116082328-B Imidazole compound and organic electroluminescent device thereof 长春海谱润斯科技股份有限公司 2025-05-27 CN disclosed
CN-115974806-B Heterocyclic compound and organic electroluminescent device thereof 长春海谱润斯科技股份有限公司 2024-09-27 CN disclosed
CN-116156921-A Organic electroluminescent device 长春海谱润斯科技股份有限公司 2023-05-23 CN disclosed
CN-116082328-A Imidazole compound and organic electroluminescent device thereof 长春海谱润斯科技股份有限公司 2023-05-09 CN disclosed
CN-109071446-B Organic reaction in aqueous solution in the presence of hydroxyalkyl (alkyl) cellulose or alkylcellulose 艾伯维德国有限责任两合公司 2022-06-21 CN disclosed
US-11065235-B2 Substituted methanopyrido [2, 1-a] isoindolones as mAChR modulators for treating various associated pathophysiological conditions and process for preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2021-07-20 US disclosed
US-11065235-B2 Substituted methanopyrido [2, 1-a] isoindolones as mAChR modulators for treating various associated pathophysiological conditions and process for preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2021-07-20 US disclosed
US-11065235-B2 Substituted methanopyrido [2, 1-a] isoindolones as mAChR modulators for treating various associated pathophysiological conditions and process for preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2021-07-20 US disclosed
EP-3625232-B1 SUBSTITUTED METHANOPYRIDO [2, 1-A]ISOINDOLONES AS MACHR MODULATORS FOR TREATING VARIOUS ASSOCIATED PATHOPHYSIOLOGICAL CONDITIONS AND PROCESS FOR PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2021-06-23 EP disclosed
EP-3221312-A2 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS Glaxosmithkline LLC (US) 2017-09-27 EP disclosed
EP-3157931-A1 CRYSTALLINE FORMS OF (2R,5S,13AR)-8-HYDROXY-7,9-DIOXO-N-(2,4,6-TRIFLUOROBENZYL)-2,3,4,5,7,9,13,13A-OCTAHYDRO-2,5-METHANOPYRIDO [1',2':4,5]PYRAZINO [2,1-B][1,3]OXAZEPINE-10-CARBOXAMIDE Gilead Sciences, Inc. (US) 2017-04-26 EP disclosed
EP-3157932-A1 SODIUM (2R, 5S, 13AR) -7, 9-DIOXO-10- ( (2,4,6-TRIFLUOROBENZYL) CARBAMOYL) -2, 3, 4, 5, 7, 9, 13, 13A-OCTAHYDRO-2, 5-METHANOPYRIDO [1',2' : 4.5]PYRAZINO [2, 1-B]OXAZEPIN-8-OLATE Gilead Sciences, Inc. (US) 2017-04-26 EP disclosed
WO-2016079709-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-05-26 WO disclosed
WO-2016081692-A2 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-05-26 WO disclosed
WO-2015196116-A1 SODIUM (2R, 5S, 13AR) -7, 9-DIOXO-10- ( (2,4,6-TRIFLUOROBENZYL) CARBAMOYL) -2, 3, 4, 5, 7, 9, 13, 13A-OCTAHYDRO-2, 5-METHANOPYRIDO [1',2' : 4.5] PYRAZINO [2, 1-B] OXAZEPIN-8-OLATE GILEAD SCIENCES, INC. (US) 2015-12-23 WO disclosed
WO-2015196137-A1 CRYSTALLINE FORMS OF (2R,5S,13AR)-8-HYDROXY-7,9-DIOXO-N-(2,4,6-TRIFLUOROBENZYL)-2,3,4,5,7,9,13,13A-OCTAHYDRO-2,5-METHANOPYRIDO [1',2':4,5] PYRAZINO [2,1-B] [1,3] OXAZEPINE-10-CARBOXAMIDE GILEAD SCIENCES, INC. (US) 2015-12-23 WO disclosed
CN-101233148-A Macrocyclic peptides as HCV NS3 protease inhibitors MERCK & CO INC (US) 2008-07-30 CN disclosed
EP-1161434-A1 PYRIDOPYRANOAZEPINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE SANOFI-SYNTHELABO (FR) 2001-12-12 EP disclosed
WO-2000053608-A1 PYRIDOPYRANOAZEPINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE SANOFI-SYNTHELABO (FR) 2000-09-14 WO disclosed